AbbVie (ABBV) Research & Development (2012 - 2026)

AbbVie (ABBV) has 15 years of Research & Development data on file, last reported at $2.5 billion in Q1 2026.

• Research & Development for Q1 2026 came in at $2.5 billion, up 19.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.5 billion (down 26.46% YoY), and the FY2025 annual result was $9.1 billion, down 28.89% from the prior year.
• Research & Development slipped to $2.5 billion in Q1 2026 per ABBV's latest filing, from $2.6 billion in the prior quarter.
• Over five years, Research & Development peaked at $6.8 billion in Q4 2024 and troughed at $1.5 billion in Q1 2022.
• A 5-year average of $2.3 billion and a median of $1.9 billion in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development soared 251.53% in 2024, then sank 61.93% in 2025.
• A 5-year view of Research & Development shows it stood at $1.8 billion in 2022, then advanced by 7.65% to $1.9 billion in 2023, then soared by 251.53% to $6.8 billion in 2024, then slumped by 61.93% to $2.6 billion in 2025, then retreated by 4.15% to $2.5 billion in 2026.
• Business Quant data shows ABBV's Research & Development at $2.5 billion in Q1 2026, $2.6 billion in Q4 2025, and $2.3 billion in Q3 2025.